GSK provides update on ContRAst phase III programme for otilimab in the treatment of moderate to severe rheumatoid arthritis
GM-CSF抗体，中重度RA临床试验数据不理想。#自身免疫性疾病# $葛兰素史克(GSK)$
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
GSK provides update on ContRAst phase III programme for otilimab in the treatment of moderate to severe rheumatoid arthritis
GM-CSF抗体，中重度RA临床试验数据不理想。#自身免疫性疾病# $葛兰素史克(GSK)$